【翰森制药：HS-20093治疗小细胞肺癌III期临床达主要终点】翰森制药公告，公司自主研发的B7-H3靶向抗体–药物偶联物HS-20093，在用于经含铂治疗后进展或复发的小细胞肺癌患者关键性III期临床试验中达到总生存期的主要终点。在预设期中分析时，与托泊替康相比，HS-20093在OS方面显示出具有统计学意义和临床意义的改善，次要终点无进展生存期亦观察到一致获益，安全性特征与既往研究结果一致。公司将于近期启动与监管机构沟通，推进在中国的新药上市申请准备工作。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.